Abstract
Historically pharmaceutical companies have handled the loss in revenue from patent expiry by developing and concentrating their focus on new drugs. With the number of new chemical entities (NCEs) b...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
